{"id":"https://openalex.org/W3143595548","doi":"https://doi.org/10.2217/imt-2021-0026","title":"Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait","display_name":"Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait","alternate_titles":[],"publication_year":2021,"publication_date":"2021-04-06","ids":{"openalex":"https://openalex.org/W3143595548","doi":"https://doi.org/10.2217/imt-2021-0026","mag":"3143595548","pmid":"https://pubmed.ncbi.nlm.nih.gov/33820447"},"language":"en","primary_location":{"id":"doi:10.2217/imt-2021-0026","doi":"https://doi.org/10.2217/imt-2021-0026","is_oa":false,"landing_page_url":"https://doi.org/10.2217/imt-2021-0026","pdf_url":null,"source":{"id":"https://openalex.org/S71887004","display_name":"Immunotherapy","issn_l":"1750-743X","issn":["1750-743X","1750-7448"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3143595548"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016268842","display_name":"Alessandro Rizzo","orcid":"https://orcid.org/0000-0002-5257-8678","observed_orcids":["https://orcid.org/0000-0002-5257-8678"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alessandro Rizzo","raw_affiliation_strings":["Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia"],"raw_orcid":"https://orcid.org/0000-0002-5257-8678","affiliations":[{"raw_affiliation_string":"Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042892518","display_name":"Angela Dalia Ricci","orcid":"https://orcid.org/0000-0002-0701-6764","observed_orcids":["https://orcid.org/0000-0002-0701-6764"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Angela Dalia Ricci","raw_affiliation_strings":["Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068055005","display_name":"Giovanni Brandi","orcid":"https://orcid.org/0000-0003-0013-2858","observed_orcids":["https://orcid.org/0000-0003-0013-2858"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Giovanni Brandi","raw_affiliation_strings":["Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni \u2013 15, Bologna, Italia","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5016268842","https://openalex.org/A5042892518"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":9.2356,"has_fulltext":false,"cited_by_count":94,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98907042,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"13","issue":"8","first_page":"637","last_page":"644"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.010099999606609344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10340","display_name":"Hepatitis B Virus Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":1.0},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.8989999890327454},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8109999895095825},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9480000138282776},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9300000071525574},{"id":"https://openalex.org/keywords/imbrave150","display_name":"IMbrave150","score":0.8740000128746033},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9309999942779541},{"id":"https://openalex.org/keywords/unresectable-liver-cancer","display_name":"unresectable liver cancer","score":0.7409999966621399},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7670000195503235},{"id":"https://openalex.org/keywords/mechanism-of-action","display_name":"mechanism of action","score":0.7319999933242798},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.949999988079071},{"id":"https://openalex.org/keywords/clinical-trial-development","display_name":"clinical trial development","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.9560014009475708},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8225172758102417},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7862637042999268},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6904614567756653},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.6463183164596558},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5731061697006226},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5460541248321533},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.51091068983078},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.4858970046043396},{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.4797574281692505},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.3844706118106842},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3167555332183838},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.29522454738616943},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19536623358726501}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.2217/imt-2021-0026","doi":"https://doi.org/10.2217/imt-2021-0026","is_oa":false,"landing_page_url":"https://doi.org/10.2217/imt-2021-0026","pdf_url":null,"source":{"id":"https://openalex.org/S71887004","display_name":"Immunotherapy","issn_l":"1750-743X","issn":["1750-743X","1750-7448"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"journal-article"},{"id":"pmid:33820447","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33820447","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:cris.unibo.it:11585/900975","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11585/900975","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W1655404187","https://openalex.org/W2066671159","https://openalex.org/W2268557403","https://openalex.org/W2279561773","https://openalex.org/W2292212945","https://openalex.org/W2564934728","https://openalex.org/W2597795073","https://openalex.org/W2606367731","https://openalex.org/W2747016053","https://openalex.org/W2770587120","https://openalex.org/W2775356055","https://openalex.org/W2805302875","https://openalex.org/W2805592007","https://openalex.org/W2883204623","https://openalex.org/W2885907209","https://openalex.org/W2890595557","https://openalex.org/W2897963483","https://openalex.org/W2903279629","https://openalex.org/W2922443161","https://openalex.org/W2947077957","https://openalex.org/W2947130797","https://openalex.org/W2965552485","https://openalex.org/W2977722669","https://openalex.org/W2979523852","https://openalex.org/W2979558918","https://openalex.org/W2985338594","https://openalex.org/W2986909458","https://openalex.org/W2998980069","https://openalex.org/W2999298357","https://openalex.org/W3012211502","https://openalex.org/W3013347515","https://openalex.org/W3020440211","https://openalex.org/W3024389603","https://openalex.org/W3025022288","https://openalex.org/W3029631869","https://openalex.org/W3033218405","https://openalex.org/W3038767246","https://openalex.org/W3042670286","https://openalex.org/W3047652909","https://openalex.org/W3048116458","https://openalex.org/W3093069491","https://openalex.org/W3093473233","https://openalex.org/W3094602125","https://openalex.org/W3106352866","https://openalex.org/W3122687696","https://openalex.org/W3123489934","https://openalex.org/W3123846806","https://openalex.org/W3128646645"],"related_works":["https://openalex.org/W3133731158","https://openalex.org/W2898153592","https://openalex.org/W2901536910","https://openalex.org/W3156792298","https://openalex.org/W4383070013","https://openalex.org/W4220849648","https://openalex.org/W2884137766","https://openalex.org/W4307723787","https://openalex.org/W4290839074","https://openalex.org/W4412808896"],"abstract_inverted_index":{"Advanced":[0],"hepatocellular":[1],"carcinoma":[2],"(HCC)":[3],"patients":[4,48],"present":[5],"poor":[6],"prognosis.":[7],"However,":[8],"recent":[9,109],"years":[10],"have":[11],"seen":[12],"the":[13,23,34,53,61,64,79,92,95,103],"advent":[14],"of":[15,25,63,77,87,97,105],"several":[16],"novel":[17],"treatments":[18],"in":[19,38,46,99],"this":[20],"setting,":[21],"where":[22],"role":[24],"immune":[26],"checkpoint":[27],"inhibitors":[28],"has":[29,42,83],"been":[30],"investigated.":[31],"Among":[32],"these,":[33],"PD-L1":[35],"inhibitor":[36],"atezolizumab":[37,98],"combination":[39,65],"with":[40,49,52],"bevacizumab":[41],"reported":[43],"unprecedented":[44],"results":[45],"treatment-naive":[47],"unresectable":[50],"disease,":[51],"recently":[54],"published":[55],"IMbrave150":[56],"Phase":[57,112],"III":[58,115],"trial":[59],"showing":[60],"superiority":[62],"over":[66],"sorafenib":[67],"monotherapy,":[68],"and":[69,94,108],"after":[70],"having":[71],"attended":[72],"more":[73],"than":[74],"a":[75,84],"decade":[76],"'stagnation',":[78],"HCC":[80],"medical":[81],"community":[82],"new":[85],"standard":[86],"care.":[88],"Herein,":[89],"we":[90],"examine":[91],"development":[93],"impact":[96],"advanced":[100],"HCC,":[101],"summarizing":[102],"mechanism":[104],"action,":[106],"pharmacokinetics":[107],"evidence":[110],"from":[111],"I":[113],"to":[114],"clinical":[116],"trials.":[117]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3143595548","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":19},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":39}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2021-04-13T00:00:00"}
